Chai Guangrui, Liu Shu, Yang Hongwei, Du Guoqiang, Chen Xiaolong
Department of Ophthalmology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Department of Geratology, The First Affiliated Hospital of China Medical University, Shenyang, Liaoning, People's Republic of China.
Diabetes Metab Syndr Obes. 2020 Aug 25;13:3047-3058. doi: 10.2147/DMSO.S264215. eCollection 2020.
Inflammation and angiogenesis are the two dominant mechanisms of diabetic retinopathy (DR), which act more as mutual pathways rather than individual processes. However, the underlying mechanism of their interactions is still unclear. Here, we explored the potential crossing points between these pathways and the targeted therapeutic method in rats with DR.
Sprague-Dawley rats were randomly assigned to four groups: normal control group, streptozocin (STZ)-induced diabetes mellitus (DM) group, DM+shNC (non-specific negative control shRNA) group, and DM+shNLRP3 group. Silencing the NLR family pyrin domain containing 3 (NLRP3) protein was performed by intravitreal injections of -targeted shRNA (shNLRP3) for rats in the DM+shNLRP3 group. All the rats' retinas were collected for further morphological examination and pro-inflammatory and pro-angiogenic cytokine detection. Human retinal endothelial cells (HRECs) were also employed to explore the underlying mechanism.
-targeted shRNA given by intravitreal injection effectively alleviated the retinal histopathological changes in STZ-induced diabetic rats, which reduced the activation of the NLRP3 inflammasome and suppressed the expressions of hypoxia-inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF), and inflammatory cytokines in diabetic rats' retinas. In HRECs, NLRP3 over-expressing plasmid evoked an increase in pro-inflammatory cytokines and VEGF. In addition, YC-1, a HIF-1α inhibitor, could reverse the NLRP3 over-expression-induced VEGF production but not the pro-inflammatory cytokine expressions.
Our results suggest NLRP3 inflammasome as the potential cross-point between inflammation and pro-angiogenesis in DR and support the effectiveness of -targeted shRNA administrated by intravitreal injection in animal models of DR. The protective effect of -targeted shRNA may stem from the inhibition of both pro-inflammatory cytokines and HIF-1α/VEGF axis.
炎症和血管生成是糖尿病视网膜病变(DR)的两种主要机制,它们更多地作为相互作用的途径而非独立过程。然而,它们相互作用的潜在机制仍不清楚。在此,我们探讨了这些途径之间的潜在交叉点以及DR大鼠的靶向治疗方法。
将Sprague-Dawley大鼠随机分为四组:正常对照组、链脲佐菌素(STZ)诱导的糖尿病(DM)组、DM + shNC(非特异性阴性对照shRNA)组和DM + shNLRP3组。通过玻璃体内注射针对大鼠的靶向shRNA(shNLRP3)使DM + shNLRP3组大鼠的含NLR家族吡咯结构域3(NLRP3)蛋白沉默。收集所有大鼠的视网膜用于进一步的形态学检查以及促炎和促血管生成细胞因子检测。还使用人视网膜内皮细胞(HREC)来探究潜在机制。
玻璃体内注射给予的靶向shRNA有效减轻了STZ诱导的糖尿病大鼠的视网膜组织病理学变化,减少了NLRP3炎性小体的激活,并抑制了糖尿病大鼠视网膜中缺氧诱导因子-1α(HIF-1α)、血管内皮生长因子(VEGF)和炎性细胞因子的表达。在HREC中,过表达NLRP3的质粒引起促炎细胞因子和VEGF增加。此外,HIF-1α抑制剂YC-1可逆转NLRP3过表达诱导的VEGF产生,但不能逆转促炎细胞因子的表达。
我们的结果表明NLRP3炎性小体是DR中炎症和促血管生成之间的潜在交叉点,并支持玻璃体内注射给予的靶向shRNA在DR动物模型中的有效性。靶向shRNA的保护作用可能源于对促炎细胞因子和HIF-1α/VEGF轴的抑制。